MedPath

Influence of Gender on the Plasma-Effect site equilibration time of propofol anesthetic and Cisatracurium Besylate neuromuscular blocking agent. A pilot study. - Gender Anesthesia

Phase 1
Conditions
effect of Gender on Pharmacokinetics of Propofol and cisatracurium
Registration Number
EUCTR2009-017921-20-AT
Lead Sponsor
niv. Klinik für Anästhesiologie
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Twenty consecutive male and twenty female, ASA I-II patients, aged 18-45 yr, undergoing general anaesthesia for scheduled elective urological or kidney surgery will be recruited in the study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Potential participants with body mass index <20 or > 26 kg/m2, or patients on treatment with drugs thought to interfere with neuromuscular transmission (aminiglycosides antibiotics, antiarrhythmics, antiepileptics, anticonvulsant, diuretics, lithium and magnesium) or patients scheduled to receive propofol Total Intravenous Anesthesia (TIVA) will be excluded from the study.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: Pharmacokinetics gender differences in Propofol and cisatracurium;Secondary Objective: None;Primary end point(s): Pharmacokinetic parameters of cisatracurium and propofol
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath